Orthofix Medical Inc. — Q3 2021 Form 10-Q
Reporting period: Three and nine months ended September 30, 2021. Orthofix is a global medical-device company focused on spine and orthopedics, selling through representatives and distributors in more than 60 countries. Amounts below are in U.S. dollars; financial figures are in millions unless stated otherwise.
Financial performance
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Net sales | $112.4 | $111.0 | $339.4 | $288.9 |
| Gross profit | $84.1 | $84.7 | $257.8 | $216.1 |
| Gross margin | 74.8% | 76.4% | 75.9% | 74.8% |
| Operating income (loss) | $(0.3) | $4.2 | $1.0 | $(10.0) |
| Net income (loss) | $(2.2) | $4.7 | $(5.6) | $11.9 |
| Diluted EPS | $(0.11) | $0.24 | $(0.28) | $0.61 |
| EBITDA, non-GAAP | $5.0 | $15.0 | $19.7 | $18.4 |
Q3 sales rose 1.3%, but gross profit declined 0.7% and the company moved from operating and net income to losses. For the first nine months, sales grew 17.5% and gross margin improved 1.1 percentage points year over year, while the company reported a net loss compared with prior-year net income.
Cash flow, liquidity and debt
- Operating cash flow for the first nine months was $6.7 million, down from $52.0 million. Capital expenditures were $12.8 million, resulting in negative free cash flow of $6.1 million, versus positive free cash flow of $39.3 million in 2020.
- Cash, cash equivalents and restricted cash totaled $83.2 million at September 30, 2021, compared with $96.8 million at December 31, 2020. Cash and cash equivalents alone were $82.7 million.
- Current assets were $260.2 million and current liabilities $80.0 million. The company had no borrowings under its secured revolving credit facility or its available Italian credit lines and was in compliance with required covenants.
- Finance lease liabilities totaled $22.6 million. The filing reports no material off-balance-sheet arrangements.
Material changes and management commentary
- Q3 Global Spine sales fell 1.9%; Global Orthopedics sales increased 13.5%. Within Spine, Spinal Implants grew 10.4%, while Bone Growth Therapies fell 4.0% and Biologics fell 16.0%.
- Management attributed Q3 declines in Bone Growth Therapies and Biologics in part to COVID-19-related restrictions on complex overnight procedures, including effects associated with the Delta variant. Orthopedics growth reflected increased international distributor orders and continued FITBONE growth.
- For the nine-month period, Global Spine sales increased 15.3% and Global Orthopedics sales increased 25.7%, reflecting recovery from pandemic-related disruption and product growth.
- Q3 gross margin fell year over year, with management citing product and geographic mix and approximately $1.0 million of higher electronic procurement costs related to the global semiconductor shortage. Research and development expense increased, including costs for European Union medical-device reporting requirements and product development.
- Q3 EBITDA fell to $5.0 million from $15.0 million. Global Spine EBITDA was $13.9 million versus $20.0 million; Global Orthopedics EBITDA was a loss of $0.2 million versus income of $1.3 million; corporate costs increased to $8.7 million from $6.2 million.
Outlook, risks and unusual items
- The filing provides no numerical full-year revenue or earnings guidance. Management said the pandemic’s future effect was uncertain, citing possible elective-procedure delays, hospital capacity constraints, patient behavior, labor availability and supply disruptions.
- The company warned that semiconductor and other component shortages could continue for several quarters or longer, with potential production delays, added costs, or product redesign and regulatory requirements. It relies on a limited number of suppliers for certain products and components.
- A $7.9 million CMS Accelerated and Advance Payment Program balance remained in current liabilities at quarter-end and is being recouped from Medicare payments. The filing reported $3.1 million of recoupment recognized in Q3 net sales.
- Spinal Kinetics contingent consideration had a $18.4 million estimated fair value at September 30. The remaining milestone is $30.0 million if achieved, or the liability will be reversed if it is not achieved within the required period; the estimate depends on future sales and procedure assumptions.
- The company accrued $7.7 million for the Italian Medical Device Payback, whose implementation remains uncertain. In Brazil, approximately $0.5 million of cash was frozen in a distributor dispute and the company accrued $0.8 million.
- A related-party transaction acquired intellectual property from a company partially owned and controlled by the CEO’s wife for up to $10.0 million: $1.0 million was paid, with up to $9.0 million contingent on milestones, plus royalties of 2%–4% of net sales. The filing states the Audit and Finance Committee supervised negotiations and the CEO was excluded from them and related oversight.
- Other unusual items included a $1.6 million non-cash foreign-currency remeasurement loss in Q3 and a favorable tax ruling that contributed a $0.3 million benefit for the nine-month period. The nine-month effective tax rate was negative 43.1% amid losses and non-deductible items.
Most important facts for investors to verify
- Whether procedure volumes and pandemic-related restrictions continue to affect Spine products and the pace of Orthopedics growth.
- Whether component shortages, supplier concentration, or procurement costs constrain production or margins.
- How CMS payment recoupments affect reported sales and cash receipts, and whether operating cash flow improves.
- Potential cash obligations and estimate sensitivity for Spinal Kinetics, the Italian payback accrual, and other contingencies.
- Terms, milestone progress, royalties, and governance disclosures for the CEO-related intellectual-property transaction.